Generic Syapse Hubspot Banners (1)

Syapse is a real-world evidence company that uses clinical expertise and advanced technologies to transform data into evidence and experience in order to improve care for patients with cancer.

Syapse works to connect comprehensive patient insights to its network and is committed to driving real impact and improving access to high-quality care through collaboration with a network of health system and life sciences partners.

VIDEO

Explore a lung cancer patient's story using real-world data

WATCH NOW
Landing Page Graphics (428 × 201 px) (6)
INFOGRAPHIC

The power of AI and clinical-genomic data to revolutionize cancer care

DOWNLOAD HERE
FACT SHEET

Learn how Syapse Cohorts enable a view into the full cancer patient's journey

LEARN MORE
LET'S MEET

Connect with us in 2023

Our team of experts is ready to learn about your oncology clinical trial, data, and research needs. Submit the contact form and we will be in touch soon.
POWERFUL SOLUTIONS

Our solutions blend seamlessly through healthcare organizations looking to transform patients’ lives using real-world evidence.

DI_Illustration-1

Data Intelligence

It is the foundation of every engagement. We bring together structured and unstructured real-world data, AI and deep knowledge to generate the kind of meaningful real-world evidence that saves lives.

IA_Illus-1

Insight Analytics

We deliver meaningful insights by combining curated patient cohorts, addressable questions through varied delivery types (e.g., customized reports, sandbox, explorer) to get you the answers you need, in the format best suited for you and your team.

AE_Illus-2

Applied Experience

Strategic collaborations between life sciences companies, molecular labs, and regulators in the Learning Health Network facilitated by Syapse’s deep partnerships with health systems. Using a proprietary approach, we address gaps in care and monitor outcomes.

RESEARCH

AstraZeneca and Syapse collaborated to uncover the risk factors for ILD associated with HER2-directed therapy in patients with metastatic breast cancer.

LEARN MORE
RESEARCH

Amgen, AdvocateAurora Health Care, and Syapse investigated the feasibility of implementing RECIST criteria in RWD in patients with metastatic NSCLC.

LEARN MORE
RESEARCH

Pfizer and Syapse identified real-world treatment patterns and clinical effectiveness of Palbociclib plus an Aromatase Inhibitor as first-line therapy in advanced metastatic breast cancer.

LEARN MORE